Learn, Analyse & Invest
only with
only with
+91
Download Orca
Venmax Drugs And Pharmaceuticals Ltd.
Venmax Drugs&Pharma
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹28.39 Cr.
| EX-Date | Purpose |
|---|---|
| 28 05 2022 | Audited Results |
| 30 07 2022 | Quarterly Results |
| 06 09 2022 | A.G.M. |
| 04 11 2022 | Quarterly Results |
| 30 01 2023 | Quarterly Results |
| 15 05 2023 | Audited Results |
| 07 08 2023 | Quarterly Results & A.G.M. |
| 11 08 2023 | Quarterly Results (Revised) |
| 14 11 2023 | Quarterly Results |
| 30 01 2024 | Quarterly Results |
| 11 11 2024 | Quarterly Results |
| 08 02 2025 | Quarterly Results |
| 09 05 2025 | Quarterly Results & Audited Results |
| 23 07 2025 | Quarterly Results |
| 16 08 2025 | Inter alia, to consider and approve Allotment of Equity Shares pursuant to conversion of Convertible Equity Share Warrants. |
| 02 09 2025 | Increase in Authorised Capital & Amalgamation & A.G.M. & Inter alia, to consider and approve:- 1. To Consider & Approve the proposal for Merger of Venmax Drugs and Pharmaceuticals Limited with M/s Hatri Pharma Private Limited. 2. To Consider and approve the Increase the Authorize Share Capital of the Company. 3. To Consider and Approve the Notice of the ensuing 36th Annual General Meeting, the Directors Report and the 36th Annual Report of the Company along with Annexures for the Financial Year 2024-25. 4. To Consider and Approve the Secretarial Auditor Report for the Financial Year 2024-2025. 5. To decide the date, time and venue of the 36th Annual General Meeting of the Company. 6. To fix the Cut-off dates for determining the E-Voting for the Annual General Meeting. 7. To consider and approve the appointment of Scrutinizer, E-Voting Agency, E-Voting Dates and other necessary authorizations for the 36th Annual General Meeting. 8. To approve the appointment Secretarial Auditors for a period of 5 consecutive financial years from 2025-26. 9. To approve the appointment of Mrs. Dakshita Jain as Additional Director, Non-Executive Independent Director. 10. Any other business as the Board deems fit to discuss, with the permission of the Chairman. |
| 12 11 2025 | Quarterly Results |
| 07 02 2026 | Quarterly Results |
News
No News data available
